Phase I study shows daratumumab plus standard myeloma therapy improves outcomes in myeloma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr María-Victoria Mateos (Hospital Universitario de Salamanca, Salamanca, Spain) discusses the open-label, multicentre, phase 1b study of daratumumab in combination with standard regimens in patients with multiple myeloma.  Standard regimens included bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.

Year of Production:
Running Time:
Color/Sound:

2014
07:05
Color/Sound

Comments are closed.